Posted On: 10/28/2016 6:04:52 PM
Post# of 658
OXPA down 62.12%
same thing with bio one wrong news and to dust or near enough ....
always take this into consideration when and if holding long JMO
plus got it got downgraded as well ...
same thing with bio one wrong news and to dust or near enough ....
always take this into consideration when and if holding long JMO
Quote:
today announced that the Phase 2b Abili-T clinical trial designed to evaluate the efficacy and safety of Tcelna® (imilecleucel-T) in patients with secondary progressive multiple sclerosis (SPMS) did not meet its primary endpoint of reduction in brain volume change (atrophy), nor did it meet the secondary endpoint of reduction of the rate of sustained disease progression. Tcelna did show a favorable safety and tolerability profile.
plus got it got downgraded as well ...
(0)
(0)
my "home" come for a visit here
Don't be afraid to be outnumbered. Pigeons flock together. Eagle fly alone
Don't be afraid to be outnumbered. Pigeons flock together. Eagle fly alone
